Publication Date
1-1-2023
Journal
Therapeutic Advances in Medical Oncology
Abstract
BACKGROUND: Recent advances have been made in targeting the phosphoinositide 3-kinase pathway in breast cancer. Phosphatase and tensin homolog (PTEN) is a key component of that pathway.
OBJECTIVE: To understand the changes in PTEN expression over the course of the disease in patients with triple-negative breast cancer (TNBC) and whether
METHODS: We compared PTEN expression by IHC between pretreatment tumors and residual tumors in the breast and lymph nodes after neoadjuvant chemotherapy in 96 patients enrolled in a TNBC clinical trial. A correlative analysis between PTEN protein expression and
RESULTS: With a stringent cutoff for PTEN IHC scoring, PTEN expression was discordant between pretreatment and posttreatment primary tumors in 5% of patients (
CONCLUSION: Testing various specimens by IHC may generate different PTEN results in a small proportion of patients with TNBC; therefore, the decision of testing one
TRIAL REGISTRATION: NCT02276443.
Keywords
ARTEMIS, PTEN, TNBC, copy number, heterogeneity, immunohistochemistry, neoadjuvant chemotherapy, next-generation sequencing